Sacral Neuromodulation for Refractory Overactive Bladder, Interstitial Cystitis, and Painful Bladder Syndrome

Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment

“…While the question of whether SNM or BTXA is the preferred third line option after failing conservative and medical therapy remains open to debate, it is likely that an individualized approach is most prudent. There remains no level I evidence to guide the clinician on the preferred third‐line treatment modality . While both BTXA and SNM have their relative benefits and drawbacks, there remains a subset of patients who may fail BTXA therapy due to either lack of efficacy, urinary retention, or adverse reaction, and are appropriate for SNM treatment.…”

“…There remains no level I evidence to guide the clinician on the preferred thirdline treatment modality. 15 While both BTXA and SNM have their relative benefits and drawbacks, there remains a subset of patients who may fail BTXA therapy due to either lack of efficacy, urinary retention, or adverse reaction, and are appropriate for SNM treatment.…”

Experience of combined pudendal and sacral electrostimulation in a patient with chronic pelvic pain

“…В настоящее время накоплен опыт, подтверждающий эффективность нейромодуляции в лечении ХТБ [10][11][12][13][14]. Так, J. Martelluci et al (2011) привели данные проспективного многоцентрового исследования метода в лечении 27 пациентов с СХТБ.…”

Sacral Neuromodulation in Urological Practice

“…9,10 The US Food and Drug Administration has approved the use of Interstim ® for the treatment of urgency-frequency syndrome, urinary urge incontinence and non-obstructive urinary retention. 11 13 In a longer-term analysis at 2 years after implantation, Siegel et al reported that the number of voids per day was significantly reduced (17.7 to 10.6; p<0.01) with 56% of patients showing 50% or greater reduction in the average voids per day, including 32% who returned to a normal range of 4 to 7 voids per day. The average volume per void significantly increased (132.5 to 225.0 ml; p<0.01) as well as improvements in the degree of urgency before voiding (p<0.01).…”